Introduction: Survivin is a nodal protein involved in several cellular pathways. It is a member of the IAP family and an integral component of the chromosomal passenger complex, where it binds to borealin and INCENP through its dimerization interface. By targeting survivin with a small molecule at its dimerization interface, inhibition of the proliferation of cancer cells has been suggested. With Abbott 8, a small-molecul e dimerization inhibitor has been recently reported. The structure–activity relationship of this series of inhibitors implied that the middle pyridin-2(1H)-one ring did not tolerate modifications of any kind. Methods: Based on the synthetic strategy of Abbott 8 using multicomponent reactions, we synthesized a series of small molecules bearing a novel rigidized core scaffold. This rigidization strategy was accomplished by integrating the pyridin-2(1H)-one and its 6-phenyl substituent into a tricyclic structure, linking position 5 of pyridin-2(1H)-one to the phenyl substituent by rings of different sizes. The new scaffolds were designed based on in silico molecular dynamics of survivin. Results: Binding of these rigidized scaffolds to the recombinant L54M mutant of survivin was evaluated, revealing affinities in the low micromolar range. Conclusion: This easily accessible, new class of survivin-dimerization modulators is an interesting starting point for further lead optimization.
CITATION STYLE
Ibrahim, T. M., Ernst, C., Lange, A., Hennig, S., & Boeckler, F. M. (2019). Small-molecule intervention at the dimerization interface of survivin by novel rigidized scaffolds. Drug Design, Development and Therapy, 13, 4247–4263. https://doi.org/10.2147/DDDT.S224561
Mendeley helps you to discover research relevant for your work.